Insider Buy/Sell Details for the Biotechnology Industry — May 2026
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (1194)
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
428
Price
$153.56
Total Value
$65.73K
Shares Held After
12
% of Holdings
97.3%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
226
Price
$152.45
Total Value
$34.45K
Shares Held After
440
% of Holdings
33.9%
RECURSION PHARMACEUTICALS, INC. (RXRX)
Gibson Christopher — Director
Shares
40,000
Price
$3.37
Total Value
$134.80K
Shares Held After
926,556
% of Holdings
4.1%
Liquidia Corp (LQDA)
JEFFS ROGER — Director
Shares
25,000
Price
$42.09
Total Value
$1.05M
Shares Held After
1,348,095
% of Holdings
1.8%
Werewolf Therapeutics, Inc. (HOWL)
EVNIN LUKE — Director
Shares
79,086
Price
$0.63
Total Value
$49.82K
Shares Held After
1,578,749
% of Holdings
4.8%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
202
Price
$597.54
Total Value
$120.70K
Shares Held After
45,172
% of Holdings
0.4%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
70
Price
$596.19
Total Value
$41.73K
Shares Held After
45,374
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
820
Price
$588.51
Total Value
$482.58K
Shares Held After
45,444
% of Holdings
1.8%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
2,970
Price
$587.61
Total Value
$1.75M
Shares Held After
46,264
% of Holdings
6.0%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
1,689
Price
$586.17
Total Value
$990.05K
Shares Held After
49,234
% of Holdings
3.3%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
994
Price
$585.18
Total Value
$581.67K
Shares Held After
50,923
% of Holdings
1.9%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
1,475
Price
$584.07
Total Value
$861.50K
Shares Held After
51,917
% of Holdings
2.8%
UNITED THERAPEUTICS Corp (UTHR)
MAHON PAUL A — EVP & GENERAL COUNSEL
Shares
80
Price
$582.86
Total Value
$46.63K
Shares Held After
53,392
% of Holdings
0.1%
Apogee Therapeutics, Inc. (APGE)
Dambkowski Carl — Chief Medical Officer
Shares
1,800
Price
$84.60
Total Value
$152.28K
Shares Held After
207,023
% of Holdings
0.9%
Apogee Therapeutics, Inc. (APGE)
Dambkowski Carl — Chief Medical Officer
Shares
3,700
Price
$83.92
Total Value
$310.50K
Shares Held After
208,823
% of Holdings
1.7%
MBX Biosciences, Inc. (MBX)
Azoulay Salomon — Chief Medical Officer
Shares
231
Price
$29.54
Total Value
$6.82K
Shares Held After
14,769
% of Holdings
1.5%
Vericel Corp (VCEL)
SIEGAL JONATHAN — Principal Accounting Officer
Shares
3,433
Price
$38.00
Total Value
$130.45K
Shares Held After
2,540
% of Holdings
57.5%
VERACYTE, INC. (VCYT)
McGuire Annie — SVP, General Counsel
Shares
5,102
Price
$40.00
Total Value
$204.08K
Shares Held After
143,708
% of Holdings
3.4%
VERACYTE, INC. (VCYT)
McGuire Annie — SVP, General Counsel
Shares
5,102
Price
$38.05
Total Value
$194.13K
Shares Held After
148,810
% of Holdings
3.3%
MBX Biosciences, Inc. (MBX)
Hawryluk P. Kent — Director
Shares
607
Price
$29.54
Total Value
$17.93K
Shares Held After
727,667
% of Holdings
0.1%
Neurogene Inc. (NGNE)
Cvijic Christine Mikail — Director
Shares
4,800
Price
$32.44
Total Value
$155.69K
Shares Held After
93,640
% of Holdings
4.9%
Neurogene Inc. (NGNE)
Cvijic Christine Mikail — Director
Shares
4,800
Price
$30.07
Total Value
$144.35K
Shares Held After
98,440
% of Holdings
4.6%
GYRE THERAPEUTICS, INC. (GYRE)
Luo Ying — Director
Shares
10,136
Price
$8.04
Total Value
$81.49K
Shares Held After
2,565,226
% of Holdings
0.4%
Liquidia Corp (LQDA)
JEFFS ROGER — Director
Shares
25,000
Price
$40.78
Total Value
$1.02M
Shares Held After
1,373,095
% of Holdings
1.8%
Werewolf Therapeutics, Inc. (HOWL)
EVNIN LUKE — Director
Shares
14,635
Price
$0.66
Total Value
$9.66K
Shares Held After
1,657,835
% of Holdings
0.9%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
100
Price
$156.00
Total Value
$15.60K
Shares Held After
666
% of Holdings
13.1%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
100
Price
$155.97
Total Value
$15.60K
Shares Held After
766
% of Holdings
11.5%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
240
Price
$154.41
Total Value
$37.06K
Shares Held After
866
% of Holdings
21.7%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
128
Price
$153.42
Total Value
$19.64K
Shares Held After
1,106
% of Holdings
10.4%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
424
Price
$152.67
Total Value
$64.73K
Shares Held After
1,234
% of Holdings
25.6%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
8
Price
$151.57
Total Value
$1.21K
Shares Held After
1,658
% of Holdings
0.5%
Avalo Therapeutics, Inc. (AVTX)
Chan Mitchell — Director
Shares
3,167
Price
$22.88
Total Value
$72.46K
Shares Held After
3,166
% of Holdings
50.0%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
8,900
Price
$22.57
Total Value
$200.91K
Shares Held After
423
% of Holdings
95.5%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
9,219
Price
$21.37
Total Value
$197.01K
Shares Held After
9,323
% of Holdings
49.7%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
2,700
Price
$20.76
Total Value
$56.05K
Shares Held After
18,542
% of Holdings
12.7%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
12,347
Price
$19.28
Total Value
$238.09K
Shares Held After
21,242
% of Holdings
36.8%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
13,834
Price
$18.55
Total Value
$256.66K
Shares Held After
33,589
% of Holdings
29.2%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
400
Price
$23.71
Total Value
$9.48K
Shares Held After
3,634
% of Holdings
9.9%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
9,253
Price
$22.70
Total Value
$210.03K
Shares Held After
4,034
% of Holdings
69.6%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
22,839
Price
$21.22
Total Value
$484.54K
Shares Held After
13,287
% of Holdings
63.2%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
5,196
Price
$19.78
Total Value
$102.78K
Shares Held After
36,126
% of Holdings
12.6%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
37,375
Price
$18.91
Total Value
$706.84K
Shares Held After
41,322
% of Holdings
47.5%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
10,058
Price
$22.88
Total Value
$230.13K
Shares Held After
3,622
% of Holdings
73.5%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
19,015
Price
$22.41
Total Value
$426.05K
Shares Held After
13,680
% of Holdings
58.2%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
44,944
Price
$21.20
Total Value
$952.67K
Shares Held After
32,695
% of Holdings
57.9%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
5,000
Price
$19.65
Total Value
$98.25K
Shares Held After
77,639
% of Holdings
6.1%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
27,538
Price
$18.03
Total Value
$496.41K
Shares Held After
82,639
% of Holdings
25.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
40
Price
$603.82
Total Value
$24.15K
Shares Held After
40,513
% of Holdings
0.1%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
80
Price
$599.26
Total Value
$47.94K
Shares Held After
40,553
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
460
Price
$598.21
Total Value
$275.17K
Shares Held After
40,633
% of Holdings
1.1%
Showing 601–650 of 1194 transactions (page 13 of 24)